CompletedPhase 3ACTRN12608000160336
A prospective study of the impact upon serum electrolyte and magnesium levels of using magnesium sulfate for bowel preparation for colonoscopy.
Sponsor
Colocap Pharmaceuticals
Enrollment
100 participants
Start Date
Feb 28, 2008
Study Type
Interventional
Conditions
Eligibility
Sex: Both males and femalesMin Age: 18 Yearss
Inclusion Criteria1
- Presenting for elective colonoscopy.
Exclusion Criteria1
- Renal insufficiency; current chronic inflammatory bowel disease.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Colocap Balance (TM) 61.75gm magnesium sulfate, encapsulated (65 capsules). Patients will take 65 capsules orally, in batches of 5 with 250ml fluid, every 15 minutes, over a period of approximately 3
Colocap Balance (TM) 61.75gm magnesium sulfate, encapsulated (65 capsules). Patients will take 65 capsules orally, in batches of 5 with 250ml fluid, every 15 minutes, over a period of approximately 3 hours.
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12608000160336
Related Trials
Electrolyte Beverage Combined With Polyethylene Glycol for Colonoscopy Bowel Preparation
NCT076081201 location
Analysis of Factors Influencing the Quality of Bowel Preparation Before Colonoscopy in IBD Patients
NCT073357051 location
Pre-packaged Low-residue Diet for Bowel Preparation in Patients With Inflammatory Bowel Disease
NCT073538531 location
Efficacy of CAD in Screening Colonoscopy to Reduce the Risk of Advanced Adenoma at 3 Years.
NCT0729907113 locations
What Influence Re-participation in the Danish Colorectal Screening Program.
NCT073536328 locations